Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons learned from clinical trials in SLE.

Vibeke Strand1

  • 1Division of Immunology and Rheumatology Stanford University, 306 Ramona Road, Portola Valley, CA 94028, United States. vstrand@aol.com

Autoimmunity Reviews
|February 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.

Annals of the rheumatic diseases·2026
Same author

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).

Rheumatology and therapy·2026
Same author

Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: long-term efficacy and safety through 5 years in the SELECT-EARLY study.

Modern rheumatology·2026
Same author

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) in Uncontrolled Gout: Current Status and Future Directions.

Drugs·2026
Same author

Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study.

Seminars in arthritis and rheumatism·2026
Same journal

Decoding gut microbiome alterations in celiac disease: Implications for pathogenesis and treatment.

Autoimmunity reviews·2026
Same journal

Rethinking immunosuppression in limited cutaneous systemic sclerosis. The lcSSc conundrum; pros and cons for a timely immunosuppressive treatment.

Autoimmunity reviews·2026
Same journal

Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomes.

Autoimmunity reviews·2026
Same journal

The role of antimicrobial peptides in rheumatoid arthritis: From mucosal predisposition to chronic synovitis.

Autoimmunity reviews·2026
Same journal

The role of short-chain fatty acids as key mediators of gut microbiota - host crosstalk in thyroid diseases.

Autoimmunity reviews·2026
Same journal

Intermittent hydrarthrosis (periodic synoviosis): A narrative review.

Autoimmunity reviews·2026
See all related articles

Assessing outcomes in Systemic Lupus Erythematosus (SLE) clinical trials is challenging due to disease complexity. However, early treatment response markers are emerging, correlating with long-term clinical outcomes and offering hope for future therapies.

Area of Science:

  • Rheumatology
  • Clinical Trial Design
  • Systemic Lupus Erythematosus (SLE) Research

Background:

  • Systemic Lupus Erythematosus (SLE) presents challenges for clinical trial outcome assessment due to its cyclic nature and multiorgan involvement.
  • Current disease activity indices and patient/physician assessments may not reliably reflect true disease outcomes within typical trial timeframes.
  • Confounding factors such as evolving medical practices and background therapies complicate the interpretation and replication of trial findings.

Purpose of the Study:

  • To address the difficulties in assessing outcomes in randomized controlled trials (RCTs) for Systemic Lupus Erythematosus (SLE).
  • To explore the development and utility of early markers for treatment response in SLE clinical trials.
  • To investigate the potential of biomarkers in evaluating treatment effects and predicting clinical outcomes in SLE.

Related Experiment Videos

Main Methods:

  • Review and analysis of existing evidence from randomized controlled trials (RCTs) in SLE.
  • Identification of challenges in outcome measure selection, reproducibility, and interpretation in SLE trials.
  • Exploration of the correlation between early treatment response markers and long-term clinical outcomes.

Main Results:

  • Despite inherent difficulties, a body of evidence from SLE RCTs has been established.
  • Early markers of treatment response have been defined and demonstrated to correlate with longer-term clinical outcomes.
  • Objective outcome measures are well-defined for specific organ systems but less so for the systemic nature of SLE.

Conclusions:

  • Assessing SLE outcomes in clinical trials requires careful protocol design that anticipates disease fluctuations and emergent manifestations.
  • While no approved therapy has yet resulted, defined early markers show promise for predicting clinical outcomes.
  • Biomarkers are a promising avenue for assessing treatment effects and predicting clinical outcomes in SLE research.